The Rheos Pivotol trial evaluating baroreflex activation therapy fails to meet efficacy and safety end points in resistant hypertension: back to the drawing board.
The Rheos Pivotol trial evaluating baroreflex activation therapy fails to meet efficacy and safety end points in resistant hypertension: back to the drawing board. J Clin Hypertens (Greenwich). 2012 Mar; 14(3):184-6.